Calliditas Therapeutics
Johan Bexelius has a diverse work experience spanning over several companies and roles. Johan is currently working at Calliditas Therapeutics as a Clinical Operations Lead Consultant. In this role, they are responsible for the execution of a clinical trial, ensuring compliance with regulations, managing study timelines and budget, and overseeing cross-functional teams.
Prior to their current position, Johan worked as a Consultant at PharmaRelations and as the Founder and Owner of J Bexelius Consulting AB. Johan also served as an Associate Director at Labcorp Drug Development in 2022.
Johan has a long history with PPD, where they held various senior management and clinical research roles. As a Senior Manager, they managed a team and played a key role in the close-out of phase III studies in Prostate Cancer. Johan also led the start-up of a global phase II study in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Johan began their career at PPD as a Clinical Research Associate before progressing to roles such as Senior Clinical Research Associate, Clinical Team Manager, and Associate Clinical Manager.
In addition, Johan had a one-year secondment as a Submission Specialist and Contract Specialist at PPD, where they coordinated submissions and amendments to ethics committees and regulatory authorities, developed informed consent forms, and facilitated contract negotiations.
Overall, Johan Bexelius has extensive experience in clinical operations, project management, and leadership roles within the pharmaceutical industry.
Johan Bexelius has a diverse education history. Johan obtained their Bachelor of Arts degree in Musicology, English, and History from Stockholm University, where they studied from 1999 to 2002. Following this, they pursued a Master of Science degree in Biomedicine at Karolinska Institutet, completing their studies from 2002 to 2006. Finally, Johan pursued their interest in Creative Writing, earning a Bachelor's Degree from Linnaeus University, where they studied from 2012 to 2015.
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.